Cell Source, Inc.

CLCS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023
Operating Activities
Net Income $-1.5M $-331.3K $-1.4M $-1.5M $-1.3M $-1.0M $-1.3M $-1.2M
Depreciation & Amortization — — — — — — — —
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation — — $5.1K $15.3K — — $26.0K $50.1K
Net Cash from Operating Activities $-600.4K $-748.3K $-639.0K $-1.1M $-173.9K $-722.3K $-280.0K $-1.0M
Investing Activities
Capital Expenditures — — — — — — — —
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities — — — — — — — —
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $527.0K $800.0K $571.5K $1.2M $151.7K $741.9K $260.6K $925.0K
Net Change in Cash $-73.4K $51.6K $-67.6K $90.5K $-22.2K $19.6K $-19.4K $-111.0K
Free Cash Flow — — — — — — — —
← Newer Page 1 of 7 Older →